{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T20:15:50Z","timestamp":1788466550468,"version":"build-2803163510"},"reference-count":118,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gut Pathog"],"DOI":"10.1186\/s13099-025-00753-w","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T06:26:21Z","timestamp":1762755981000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Progress and prospects of gut microbiota-targeted therapy for primary biliary cholangitis"],"prefix":"10.1186","volume":"17","author":[{"given":"Xuan","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"issue":"10457","key":"753_CR1","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/S0140-6736(24)01303-5","volume":"404","author":"A Tanaka","year":"2024","unstructured":"Tanaka A, Ma X, et al. Primary biliary cholangitis. Lancet. 2024;404(10457):1053\u201366.","journal-title":"Lancet"},{"issue":"2","key":"753_CR2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41575-019-0226-7","volume":"17","author":"AF Gulamhusein","year":"2020","unstructured":"Gulamhusein AF, Hirschfield GM. Primary biliary cholangitis: pathogenesis and therapeutic opportunities. Nat Rev Gastroenterol Hepatol. 2020;17(2):93\u2013110.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"753_CR3","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.cld.2022.06.001","volume":"26","author":"F Colapietro","year":"2022","unstructured":"Colapietro F, Bertazzoni A, et al. Contemporary epidemiology of primary biliary cholangitis. Clin Liver Dis. 2022;26(4):555\u201370.","journal-title":"Clin Liver Dis"},{"issue":"8","key":"753_CR4","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1016\/j.cgh.2023.02.005","volume":"21","author":"C Levy","year":"2023","unstructured":"Levy C, Manns M, et al. New treatment paradigms in primary biliary cholangitis. Clin Gastroenterol Hepatol. 2023;21(8):2076\u201387.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"753_CR5","doi-asserted-by":"crossref","unstructured":"LAMMERS W J, VAN BUUREN H R, et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study [J]. Gastroenterology, 2014, 147(6): 1338-49.e5; quiz e15.","DOI":"10.1053\/j.gastro.2014.10.032"},{"issue":"1","key":"753_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40265-023-01979-1","volume":"84","author":"A Tanaka","year":"2024","unstructured":"Tanaka A. New therapies on the horizon for primary biliary cholangitis. Drugs. 2024;84(1):1\u201315.","journal-title":"Drugs"},{"issue":"4","key":"753_CR7","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","volume":"148","author":"GM Hirschfield","year":"2015","unstructured":"Hirschfield GM, Mason A, et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid [J]. Gastroenterology. 2015;148(4):751-61.e8.","journal-title":"Gastroenterology"},{"issue":"6","key":"753_CR8","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S2468-1253(19)30094-9","volume":"4","author":"M Trauner","year":"2019","unstructured":"Trauner M, Nevens F, et al. Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study. Lancet Gastroenterol Hepatol. 2019;4(6):445\u201353.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"753_CR9","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1002\/hep.29569","volume":"67","author":"KV Kowdley","year":"2018","unstructured":"Kowdley KV, Luketic V, et al. A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. Hepatology. 2018;67(5):1890\u2013902.","journal-title":"Hepatology"},{"issue":"7","key":"753_CR10","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1056\/NEJMoa1509840","volume":"375","author":"F Nevens","year":"2016","unstructured":"Nevens F, Andreone P, et al. A placebo-controlled trial of Obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016;375(7):631\u201343.","journal-title":"N Engl J Med"},{"issue":"2","key":"753_CR11","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1002\/hep.27744","volume":"62","author":"NS Ghonem","year":"2015","unstructured":"Ghonem NS, Assis DN, et al. Fibrates and cholestasis. Hepatology. 2015;62(2):635\u201343.","journal-title":"Hepatology"},{"issue":"3","key":"753_CR12","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1053\/j.gastro.2020.10.001","volume":"160","author":"E de Vries","year":"2021","unstructured":"de Vries E, Bolier R, et al. Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled Trial [J]. Gastroenterology. 2021;160(3):734-43.e6.","journal-title":"Gastroenterology"},{"issue":"6","key":"753_CR13","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1111\/liv.14871","volume":"41","author":"AF Carrion","year":"2021","unstructured":"Carrion AF, Lindor KD, et al. Safety of fibrates in cholestatic liver diseases. Liver Int. 2021;41(6):1335\u201343.","journal-title":"Liver Int"},{"key":"753_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21062061","author":"Y Wang","year":"2020","unstructured":"Wang Y, Nakajima T, et al. Ppars as metabolic regulators in the liver: lessons from liver-specific PPAR-null mice. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21062061.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"753_CR15","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2306185","volume":"390","author":"KV Kowdley","year":"2024","unstructured":"Kowdley KV, Bowlus CL, et al. Efficacy and safety of elafibranor in primary biliary cholangitis. N Engl J Med. 2024;390(9):795\u2013805.","journal-title":"N Engl J Med"},{"issue":"9","key":"753_CR16","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJMoa2312100","volume":"390","author":"GM Hirschfield","year":"2024","unstructured":"Hirschfield GM, Bowlus CL, et al. A phase 3 trial of Seladelpar in primary biliary cholangitis. N Engl J Med. 2024;390(9):783\u201394.","journal-title":"N Engl J Med"},{"issue":"3","key":"753_CR17","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s00018-018-2943-4","volume":"76","author":"A Adak","year":"2019","unstructured":"Adak A, Khan MR. An insight into gut microbiota and its functionalities. Cell Mol Life Sci. 2019;76(3):473\u201393.","journal-title":"Cell Mol Life Sci"},{"key":"753_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.746998","volume":"12","author":"Q Xu","year":"2021","unstructured":"Xu Q, Ni JJ, et al. Causal Relationship Between Gut Microbiota and Autoimmune Diseases: A Two-Sample Mendelian Randomization Study [J]. Front Immunol. 2021;12:746998.","journal-title":"Front Immunol"},{"issue":"4","key":"753_CR19","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1038\/s41423-021-00661-4","volume":"18","author":"W Yang","year":"2021","unstructured":"Yang W, Cong Y. Gut microbiota-derived metabolites in the regulation of host immune responses and immune-related inflammatory diseases. Cell Mol Immunol. 2021;18(4):866\u201377.","journal-title":"Cell Mol Immunol"},{"key":"753_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.946248","volume":"13","author":"A Christovich","year":"2022","unstructured":"Christovich A, Luo XM. Gut microbiota, leaky gut, and autoimmune diseases. Front Immunol. 2022;13:946248.","journal-title":"Front Immunol"},{"key":"753_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102844","volume":"130","author":"C Huang","year":"2022","unstructured":"Huang C, Yi P, et al. Safety and efficacy of fecal microbiota transplantation for treatment of systemic lupus erythematosus: an EXPLORER trial. J Autoimmun. 2022;130:102844.","journal-title":"J Autoimmun"},{"issue":"7","key":"753_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0198757","volume":"13","author":"K Abe","year":"2018","unstructured":"Abe K, Takahashi A, et al. Dysbiosis of oral microbiota and its association with salivary immunological biomarkers in autoimmune liver disease. PLoS ONE. 2018;13(7):e0198757.","journal-title":"PLoS ONE"},{"issue":"3","key":"753_CR23","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1136\/gutjnl-2016-313332","volume":"67","author":"R Tang","year":"2018","unstructured":"Tang R, Wei Y, et al. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy. Gut. 2018;67(3):534\u201341.","journal-title":"Gut"},{"issue":"7","key":"753_CR24","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/hepr.13509","volume":"50","author":"M Furukawa","year":"2020","unstructured":"Furukawa M, Moriya K, et al. Gut dysbiosis associated with clinical prognosis of patients with primary biliary cholangitis. Hepatol Res. 2020;50(7):840\u201352.","journal-title":"Hepatol Res"},{"issue":"1","key":"753_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-99314-9","volume":"11","author":"S Kitahata","year":"2021","unstructured":"Kitahata S, Yamamoto Y, et al. Ileal mucosa-associated microbiota overgrowth associated with pathogenesis of primary biliary cholangitis. Sci Rep. 2021;11(1):19705.","journal-title":"Sci Rep"},{"issue":"1","key":"753_CR26","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2023.2208501","volume":"15","author":"L Martinez-Gili","year":"2023","unstructured":"Martinez-Gili L, Pechlivanis A, et al. Bacterial and metabolic phenotypes associated with inadequate response to ursodeoxycholic acid treatment in primary biliary cholangitis. Gut Microbes. 2023;15(1):2208501.","journal-title":"Gut Microbes"},{"key":"753_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.946628","volume":"13","author":"H Guan","year":"2022","unstructured":"Guan H, Zhang X, et al. The gut-liver axis in immune remodeling of hepatic cirrhosis. Front Immunol. 2022;13:946628.","journal-title":"Front Immunol"},{"issue":"9","key":"753_CR28","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.autrev.2017.07.002","volume":"16","author":"Y Li","year":"2017","unstructured":"Li Y, Tang R, et al. Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases. Autoimmun Rev. 2017;16(9):885\u201396.","journal-title":"Autoimmun Rev"},{"issue":"3","key":"753_CR29","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1055\/s-0034-1383729","volume":"34","author":"L Wang","year":"2014","unstructured":"Wang L, Wang FS, et al. Breach of tolerance: primary biliary cirrhosis [J]. Semin Liver Dis. 2014;34(3):297\u2013317.","journal-title":"Semin Liver Dis"},{"issue":"3","key":"753_CR30","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.autrev.2014.10.013","volume":"14","author":"HD Ma","year":"2015","unstructured":"Ma HD, Wang YH, et al. The intestinal microbiota and microenvironment in liver. Autoimmun Rev. 2015;14(3):183\u201391.","journal-title":"Autoimmun Rev"},{"key":"753_CR31","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1146\/annurev.immunol.21.120601.141122","volume":"22","author":"S Sakaguchi","year":"2004","unstructured":"Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol. 2004;22:531\u201362.","journal-title":"Annu Rev Immunol"},{"issue":"21","key":"753_CR32","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.3748\/wjg.v26.i21.2768","volume":"26","author":"R Little","year":"2020","unstructured":"Little R, Wine E, et al. Gut microbiome in primary sclerosing cholangitis: a review. World J Gastroenterol. 2020;26(21):2768\u201380.","journal-title":"World J Gastroenterol"},{"issue":"6086","key":"753_CR33","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1126\/science.1223490","volume":"336","author":"LV Hooper","year":"2012","unstructured":"Hooper LV, Littman DR, et al. Interactions between the microbiota and the immune system. Science. 2012;336(6086):1268\u201373.","journal-title":"Science"},{"key":"753_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108273","volume":"239","author":"T Ikeda","year":"2022","unstructured":"Ikeda T, Nishida A, et al. Short-chain fatty acid receptors and gut microbiota as therapeutic targets in metabolic, immune, and neurological diseases. Pharmacol Ther. 2022;239:108273.","journal-title":"Pharmacol Ther"},{"issue":"10","key":"753_CR35","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/nri3738","volume":"14","author":"AM Mowat","year":"2014","unstructured":"Mowat AM, Agace WW. Regional specialization within the intestinal immune system. Nat Rev Immunol. 2014;14(10):667\u201385.","journal-title":"Nat Rev Immunol"},{"key":"753_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/srep16148","volume":"5","author":"C Nastasi","year":"2015","unstructured":"Nastasi C, Candela M, et al. The effect of short-chain fatty acids on human monocyte-derived dendritic cells. Sci Rep. 2015;5:16148.","journal-title":"Sci Rep"},{"issue":"9","key":"753_CR37","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.3945\/jn.109.104638","volume":"139","author":"L Peng","year":"2009","unstructured":"Peng L, Li ZR, et al. Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J Nutr. 2009;139(9):1619\u201325.","journal-title":"J Nutr"},{"issue":"12","key":"753_CR38","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1007\/s10620-012-2259-4","volume":"57","author":"HB Wang","year":"2012","unstructured":"Wang HB, Wang PY, et al. Butyrate enhances intestinal epithelial barrier function via up-regulation of tight junction protein Claudin-1 transcription. Dig Dis Sci. 2012;57(12):3126\u201335.","journal-title":"Dig Dis Sci"},{"issue":"1","key":"753_CR39","doi-asserted-by":"publisher","first-page":"2383353","DOI":"10.1080\/19490976.2024.2383353","volume":"16","author":"H Jiang","year":"2024","unstructured":"Jiang H, Yu Y, et al. The fecal microbiota of patients with primary biliary cholangitis (PBC) causes PBC-like liver lesions in mice and exacerbates liver damage in a mouse model of PBC [J]. Gut Microbes. 2024;16(1):2383353.","journal-title":"Gut Microbes"},{"issue":"4","key":"753_CR40","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1053\/j.gastro.2024.05.014","volume":"167","author":"R Wang","year":"2024","unstructured":"Wang R, Li B, et al. Gut Microbiota-Derived Butyrate Induces Epigenetic and Metabolic Reprogramming in Myeloid-Derived Suppressor Cells to Alleviate Primary Biliary Cholangitis [J]. Gastroenterology. 2024;167(4):733-49.e3.","journal-title":"Gastroenterology"},{"issue":"3","key":"753_CR41","doi-asserted-by":"publisher","first-page":"G171","DOI":"10.1152\/ajpgi.00048.2015","volume":"312","author":"JM Wells","year":"2017","unstructured":"Wells JM, Brummer RJ, et al. Homeostasis of the gut barrier and potential biomarkers [J]. Am J Physiol Gastrointest Liver Physiol. 2017;312(3):G171\u201393.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"1\u20132","key":"753_CR42","doi-asserted-by":"publisher","DOI":"10.4161\/21688370.2014.982426","volume":"3","author":"S Cornick","year":"2015","unstructured":"Cornick S, Tawiah A, et al. Roles and regulation of the mucus barrier in the gut. Tissue Barriers. 2015;3(1\u20132):e982426.","journal-title":"Tissue Barriers"},{"key":"753_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/nu10080988","author":"K Hiippala","year":"2018","unstructured":"Hiippala K, Jouhten H, et al. The potential of gut commensals in reinforcing intestinal barrier function and alleviating inflammation. Nutrients. 2018. https:\/\/doi.org\/10.3390\/nu10080988.","journal-title":"Nutrients"},{"issue":"2","key":"753_CR44","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/hep.22034","volume":"47","author":"B Gao","year":"2008","unstructured":"Gao B, Jeong WI, et al. Liver: An organ with predominant innate immunity [J]. Hepatology. 2008;47(2):729\u201336.","journal-title":"Hepatology"},{"issue":"3","key":"753_CR45","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1053\/j.gastro.2020.04.077","volume":"159","author":"DM Chopyk","year":"2020","unstructured":"Chopyk DM, Grakoui A. Contribution of the intestinal microbiome and gut barrier to hepatic disorders. Gastroenterology. 2020;159(3):849\u201363.","journal-title":"Gastroenterology"},{"issue":"3","key":"753_CR46","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/s41564-018-0333-1","volume":"4","author":"N Nakamoto","year":"2019","unstructured":"Nakamoto N, Sasaki N, et al. Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis. Nat Microbiol. 2019;4(3):492\u2013503.","journal-title":"Nat Microbiol"},{"issue":"2","key":"753_CR47","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0168-8278(01)00084-8","volume":"35","author":"K Tsuneyama","year":"2001","unstructured":"Tsuneyama K, Harada K, et al. Scavenger cells with gram-positive bacterial lipoteichoic acid infiltrate around the damaged interlobular bile ducts of primary biliary cirrhosis. J Hepatol. 2001;35(2):156\u201363.","journal-title":"J Hepatol"},{"issue":"5","key":"753_CR48","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.jhep.2023.12.023","volume":"80","author":"TS Andrews","year":"2024","unstructured":"Andrews TS, Nakib D, et al. Single-cell, single-nucleus, and spatial transcriptomics characterization of the immunological landscape in the healthy and PSC human liver. J Hepatol. 2024;80(5):730\u201343.","journal-title":"J Hepatol"},{"key":"753_CR49","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jaut.2018.09.010","volume":"95","author":"HD Ma","year":"2018","unstructured":"Ma HD, Zhao ZB, et al. Gut microbiota translocation promotes autoimmune cholangitis. J Autoimmun. 2018;95:47\u201357.","journal-title":"J Autoimmun"},{"key":"753_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25084321","author":"Z Guo","year":"2024","unstructured":"Guo Z, He K, et al. Exploring advanced therapies for primary biliary cholangitis: insights from the gut microbiota-bile acid-immunity network. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25084321.","journal-title":"Int J Mol Sci"},{"key":"753_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01853","volume":"9","author":"S Fiorucci","year":"2018","unstructured":"Fiorucci S, Biagioli M, et al. Bile acids activated receptors regulate innate immunity. Front Immunol. 2018;9:1853.","journal-title":"Front Immunol"},{"key":"753_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108238","volume":"237","author":"J Cai","year":"2022","unstructured":"Cai J, Rimal B, et al. Bile acid metabolism and signaling, the microbiota, and metabolic disease. Pharmacol Ther. 2022;237:108238.","journal-title":"Pharmacol Ther"},{"issue":"4","key":"753_CR53","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1002\/hep.27964","volume":"62","author":"JY Chiang","year":"2015","unstructured":"Chiang JY. Negative feedback regulation of bile acid metabolism: impact on liver metabolism and diseases. Hepatology. 2015;62(4):1315\u20137.","journal-title":"Hepatology"},{"issue":"2","key":"753_CR54","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.cmet.2013.01.003","volume":"17","author":"SI Sayin","year":"2013","unstructured":"Sayin SI, WAHLSTR\u00f6M A, et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 2013;17(2):225.","journal-title":"Cell Metab"},{"issue":"4","key":"753_CR55","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41579-022-00805-x","volume":"21","author":"SL Collins","year":"2023","unstructured":"Collins SL, Stine JG, et al. Bile acids and the gut microbiota: metabolic interactions and impacts on disease. Nat Rev Microbiol. 2023;21(4):236\u201347.","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"753_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17183-8","volume":"11","author":"N van Best","year":"2020","unstructured":"van Best N, Rolle-Kampczyk U, et al. Bile acids drive the newborn\u2019s gut microbiota maturation. Nat Commun. 2020;11(1):3692.","journal-title":"Nat Commun"},{"issue":"4","key":"753_CR57","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1080\/19490976.2020.1732268","volume":"11","author":"Y Tian","year":"2020","unstructured":"Tian Y, Gui W, et al. The microbiome modulating activity of bile acids. Gut Microbes. 2020;11(4):979\u201396.","journal-title":"Gut Microbes"},{"issue":"9","key":"753_CR58","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1038\/s42255-021-00452-1","volume":"3","author":"KM Schneider","year":"2021","unstructured":"Schneider KM, Candels LS, et al. Gut microbiota depletion exacerbates cholestatic liver injury via loss of FXR signalling. Nat Metab. 2021;3(9):1228\u201341.","journal-title":"Nat Metab"},{"issue":"6","key":"753_CR59","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1002\/hep.20491","volume":"40","author":"TK Mao","year":"2004","unstructured":"Mao TK, Davis PA, et al. Sidechain biology and the immunogenicity of PDC-E2, the major autoantigen of primary biliary cirrhosis. Hepatology. 2004;40(6):1241\u20138.","journal-title":"Hepatology"},{"issue":"4","key":"753_CR60","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.jaut.2006.11.004","volume":"27","author":"J Allina","year":"2006","unstructured":"Allina J, Hu B, et al. T cell targeting and phagocytosis of apoptotic biliary epithelial cells in primary biliary cirrhosis. J Autoimmun. 2006;27(4):232\u201341.","journal-title":"J Autoimmun"},{"key":"753_CR61","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev-pathol-020712-164014","volume":"8","author":"GM Hirschfield","year":"2013","unstructured":"Hirschfield GM, Gershwin ME. The immunobiology and pathophysiology of primary biliary cirrhosis. Annu Rev Pathol. 2013;8:303\u201330.","journal-title":"Annu Rev Pathol"},{"issue":"4","key":"753_CR62","first-page":"958","volume":"11","author":"L Zhang","year":"2023","unstructured":"Zhang L, Yang L, et al. Targeting Gut Microbiota for the Treatment of Primary Biliary Cholangitis: From Bench to Bedside [J]. J Clin Transl Hepatol. 2023;11(4):958\u201366.","journal-title":"J Clin Transl Hepatol"},{"issue":"1","key":"753_CR63","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0168-8278(03)00501-4","volume":"40","author":"DP Bogdanos","year":"2004","unstructured":"Bogdanos DP, Baum H, et al. Microbial mimics are major targets of crossreactivity with human pyruvate dehydrogenase in primary biliary cirrhosis. J Hepatol. 2004;40(1):31\u20139.","journal-title":"J Hepatol"},{"issue":"5","key":"753_CR64","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1053\/jhep.2003.50446","volume":"38","author":"C Selmi","year":"2003","unstructured":"Selmi C, Balkwill DL, et al. Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. Hepatology. 2003;38(5):1250\u20137.","journal-title":"Hepatology"},{"issue":"6","key":"753_CR65","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1053\/j.gastro.2024.01.049","volume":"166","author":"PJ Trivedi","year":"2024","unstructured":"Trivedi PJ, Hirschfield GM, et al. Immunopathogenesis of primary biliary cholangitis, primary sclerosing cholangitis and autoimmune hepatitis: themes and concepts. Gastroenterology. 2024;166(6):995\u20131019.","journal-title":"Gastroenterology"},{"issue":"2","key":"753_CR66","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/cei.12224","volume":"175","author":"JJ Wang","year":"2014","unstructured":"Wang JJ, Yang GX, Zhang WC, et al. Escherichia coli infection induces autoimmune cholangitis and anti-mitochondrial antibodies in non-obese diabetic (NOD).B6 (Idd10\/Idd18) mice. Clin Exp Immunol. 2014;175(2):192\u2013201.","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"753_CR67","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jhep.2010.02.019","volume":"53","author":"C Corpechot","year":"2010","unstructured":"Corpechot C, CHR\u00e9TIEN Y, et al. Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis. J Hepatol. 2010;53(1):162\u20139.","journal-title":"J Hepatol"},{"issue":"2","key":"753_CR68","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1136\/gut.25.2.133","volume":"25","author":"AK Burroughs","year":"1984","unstructured":"Burroughs AK, Rosenstein IJ, et al. Bacteriuria and primary biliary cirrhosis [J]. Gut. 1984;25(2):133\u20137.","journal-title":"Gut"},{"issue":"2","key":"753_CR69","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/hep.510280207","volume":"28","author":"B Terjung","year":"1998","unstructured":"Terjung B, Herzog V, et al. Atypical antineutrophil cytoplasmic antibodies with perinuclear fluorescence in chronic inflammatory bowel diseases and hepatobiliary disorders colocalize with nuclear lamina proteins. Hepatology. 1998;28(2):332\u201340.","journal-title":"Hepatology"},{"issue":"3","key":"753_CR70","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/hep.1840170310","volume":"17","author":"AH Mulder","year":"1993","unstructured":"Mulder AH, Horst G, et al. Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases. Hepatology. 1993;17(3):411\u20137.","journal-title":"Hepatology"},{"issue":"6","key":"753_CR71","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1136\/gut.2008.157818","volume":"59","author":"B Terjung","year":"2010","unstructured":"Terjung B, S\u00f6HNE J, et al. p-ANCAs in autoimmune liver disorders recognise human beta-tubulin isotype 5 and cross-react with microbial protein FtsZ [J]. Gut. 2010;59(6):808\u201316.","journal-title":"Gut"},{"issue":"6","key":"753_CR72","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/apt.12232","volume":"37","author":"JH Tabibian","year":"2013","unstructured":"Tabibian JH, Weeding E, et al. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study [J]. Aliment Pharmacol Ther. 2013;37(6):604\u201312.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"753_CR73","doi-asserted-by":"publisher","first-page":"457","DOI":"10.15403\/jgld.2014.1121.254.rah","volume":"25","author":"S Rahimpour","year":"2016","unstructured":"Rahimpour S, Nasiri-Toosi M, et al. A triple blinded, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of oral vancomycin in primary sclerosing cholangitis: a pilot study. J Gastrointestin Liver Dis. 2016;25(4):457\u201364.","journal-title":"J Gastrointestin Liver Dis"},{"issue":"1","key":"753_CR74","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1097\/MJT.0000000000000102","volume":"24","author":"JH Tabibian","year":"2017","unstructured":"Tabibian JH, Gossard A, et al. Prospective Clinical Trial of Rifaximin Therapy for Patients With Primary Sclerosing Cholangitis [J]. Am J Ther. 2017;24(1):e56\u201363.","journal-title":"Am J Ther"},{"issue":"6","key":"753_CR75","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1002\/hep.20457","volume":"40","author":"M F\u00e4RKKIL\u00e4","year":"2004","unstructured":"F\u00e4RKKIL\u00e4 M, Karvonen AL, et al. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology. 2004;40(6):1379\u201386.","journal-title":"Hepatology"},{"issue":"2","key":"753_CR76","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.jhep.2016.09.020","volume":"66","author":"E Schrumpf","year":"2017","unstructured":"Schrumpf E, Kummen M, et al. The gut microbiota contributes to a mouse model of spontaneous bile duct inflammation. J Hepatol. 2017;66(2):382\u20139.","journal-title":"J Hepatol"},{"issue":"9","key":"753_CR77","doi-asserted-by":"publisher","first-page":"507","DOI":"10.21037\/atm-21-5448","volume":"10","author":"CB Wang","year":"2022","unstructured":"Wang CB, Wang Y, et al. The gut microbiome contributes to splenomegaly and tissue inflammation in a murine model of primary biliary cholangitis. Ann Transl Med. 2022;10(9):507.","journal-title":"Ann Transl Med"},{"issue":"22","key":"753_CR78","doi-asserted-by":"publisher","first-page":"6327","DOI":"10.1016\/j.cell.2024.08.038","volume":"187","author":"EJ Culp","year":"2024","unstructured":"Culp EJ, Nelson NT, et al. Microbial transformation of dietary xenobiotics shapes gut microbiome composition [J]. Cell. 2024;187(22):6327-45.e20.","journal-title":"Cell"},{"issue":"12","key":"753_CR79","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1017\/S0007114517001593","volume":"117","author":"EK Mitsou","year":"2017","unstructured":"Mitsou EK, Kakali A, et al. Adherence to the Mediterranean diet is associated with the gut microbiota pattern and gastrointestinal characteristics in an adult population. Br J Nutr. 2017;117(12):1645\u201355.","journal-title":"Br J Nutr"},{"key":"753_CR80","doi-asserted-by":"publisher","DOI":"10.3390\/nu14153186","author":"S Montemayor","year":"2022","unstructured":"Montemayor S, MASCAR\u00f3 CM, et al. Adherence to Mediterranean diet and NAFLD in patients with metabolic syndrome: the FLIPAN study. Nutrients. 2022. https:\/\/doi.org\/10.3390\/nu14153186.","journal-title":"Nutrients"},{"issue":"2","key":"753_CR81","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1017\/S000711451800137X","volume":"120","author":"CN Katsagoni","year":"2018","unstructured":"Katsagoni CN, Papatheodoridis GV, et al. Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: a randomised controlled clinical trial. Br J Nutr. 2018;120(2):164\u201375.","journal-title":"Br J Nutr"},{"issue":"16","key":"753_CR82","doi-asserted-by":"publisher","first-page":"4137","DOI":"10.1016\/j.cell.2021.06.019","volume":"184","author":"HC Wastyk","year":"2021","unstructured":"Wastyk HC, Fragiadakis GK, et al. Gut-microbiota-targeted diets modulate human immune status [J]. Cell. 2021;184(16):4137-53.e14.","journal-title":"Cell"},{"issue":"9","key":"753_CR83","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1017\/S0007114518002465","volume":"120","author":"D Lin","year":"2018","unstructured":"Lin D, Peters BA, et al. Association of dietary fibre intake and gut microbiota in adults. Br J Nutr. 2018;120(9):1014\u201322.","journal-title":"Br J Nutr"},{"issue":"2","key":"753_CR84","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41575-020-00375-4","volume":"18","author":"SK Gill","year":"2021","unstructured":"Gill SK, Rossi M, et al. Dietary fibre in gastrointestinal health and disease. Nat Rev Gastroenterol Hepatol. 2021;18(2):101\u201316.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"753_CR85","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.chom.2018.05.012","volume":"23","author":"K Makki","year":"2018","unstructured":"Makki K, Deehan EC, et al. The impact of dietary fiber on gut microbiota in host health and disease. Cell Host Microbe. 2018;23(6):705\u201315.","journal-title":"Cell Host Microbe"},{"issue":"1","key":"753_CR86","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1017\/S0029665114001463","volume":"74","author":"HJ Flint","year":"2015","unstructured":"Flint HJ, Duncan SH, et al. Links between diet, gut microbiota composition and gut metabolism [J]. Proc Nutr Soc. 2015;74(1):13\u201322.","journal-title":"Proc Nutr Soc"},{"issue":"6145","key":"753_CR87","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1126\/science.1241165","volume":"341","author":"PM Smith","year":"2013","unstructured":"Smith PM, Howitt MR, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science. 2013;341(6145):569\u201373.","journal-title":"Science"},{"issue":"1","key":"753_CR88","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-03135-8","volume":"21","author":"J Orliacq","year":"2023","unstructured":"Orliacq J, P\u00e9REZ-CORNAGO A, et al. Associations between types and sources of dietary carbohydrates and liver fat: a UK Biobank study. BMC Med. 2023;21(1):444.","journal-title":"BMC Med"},{"issue":"6","key":"753_CR89","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.cell.2020.04.027","volume":"181","author":"QY Ang","year":"2020","unstructured":"Ang QY, Alexander M, et al. Ketogenic Diets Alter the Gut Microbiome Resulting in Decreased Intestinal Th17 Cells [J]. Cell. 2020;181(6):1263-75.e16.","journal-title":"Cell"},{"issue":"10344","key":"753_CR90","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1016\/S0140-6736(22)00794-2","volume":"399","author":"C Catassi","year":"2022","unstructured":"Catassi C, Verdu EF, et al. Coeliac disease. Lancet. 2022;399(10344):2413\u201326.","journal-title":"Lancet"},{"key":"753_CR91","unstructured":"Xin L. (2024) Preliminary exploration of gluten-free and hypoallergenic diet for improving primary biliary cholangitis by targeting intestinal flora[D]"},{"issue":"2","key":"753_CR92","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/apt.17256","volume":"57","author":"T Liwinski","year":"2023","unstructured":"Liwinski T, H\u00fcBENER S, et al. A prospective pilot study of a gluten-free diet for primary sclerosing cholangitis and associated colitis. Aliment Pharmacol Ther. 2023;57(2):224\u201336.","journal-title":"Aliment Pharmacol Ther"},{"key":"753_CR93","doi-asserted-by":"crossref","unstructured":"Hill C Guarner F, et al. (2014) Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic [J]. Nat Rev Gastroenterol Hepatol 11(8) 506 14.","DOI":"10.1038\/nrgastro.2014.66"},{"issue":"1","key":"753_CR94","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.celrep.2014.02.032","volume":"7","author":"C Degirolamo","year":"2014","unstructured":"Degirolamo C, Rainaldi S, et al. Microbiota modification with probiotics induces hepatic bile acid synthesis via downregulation of the Fxr-Fgf15 axis in mice. Cell Rep. 2014;7(1):12\u20138.","journal-title":"Cell Rep"},{"issue":"6","key":"753_CR95","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1002\/hep.30975","volume":"71","author":"Y Liu","year":"2020","unstructured":"Liu Y, Chen K, et al. Probiotic Lactobacillus rhamnosus GG prevents liver fibrosis through inhibiting hepatic bile acid synthesis and enhancing bile acid excretion in mice [J]. Hepatology. 2020;71(6):2050\u201366.","journal-title":"Hepatology"},{"issue":"1","key":"753_CR96","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2024.2390176","volume":"16","author":"L Wu","year":"2024","unstructured":"Wu L, Zhou J, et al. Lactobacillus acidophilus ameliorates cholestatic liver injury through inhibiting bile acid synthesis and promoting bile acid excretion. Gut Microbes. 2024;16(1):2390176.","journal-title":"Gut Microbes"},{"key":"753_CR97","doi-asserted-by":"publisher","DOI":"10.3390\/nu15234864","author":"S Han","year":"2023","unstructured":"Han S, Wang K, et al. Probiotic Pediococcus pentosaceus Li05 improves cholestasis through the FXR-SHP and FXR-FGF15 pathways. Nutrients. 2023. https:\/\/doi.org\/10.3390\/nu15234864.","journal-title":"Nutrients"},{"issue":"9","key":"753_CR98","doi-asserted-by":"publisher","DOI":"10.3390\/nu13093192","volume":"13","author":"MH Mohamad Nor","year":"2021","unstructured":"Mohamad Nor MH, Ayob N, et al. The effect of probiotics (MCP(\u00ae) BCMC(\u00ae) strains) on hepatic steatosis, small intestinal mucosal immune function, and intestinal barrier in patients with non-alcoholic fatty liver disease. Nutrients. 2021;13(9):3192.","journal-title":"Nutrients"},{"issue":"2","key":"753_CR99","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.alcohol.2008.12.009","volume":"43","author":"CB Forsyth","year":"2009","unstructured":"Forsyth CB, Farhadi A, et al. Lactobacillus GG treatment ameliorates alcohol-induced intestinal oxidative stress, gut leakiness, and liver injury in a rat model of alcoholic steatohepatitis. Alcohol. 2009;43(2):163\u201372.","journal-title":"Alcohol"},{"issue":"6","key":"753_CR100","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.cgh.2013.11.006","volume":"12","author":"MK Lunia","year":"2014","unstructured":"Lunia MK, Sharma BC, et al. Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial [J]. Clin Gastroenterol Hepatol. 2014;12(6):1003-8.e1.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"753_CR101","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1111\/apt.12695","volume":"39","author":"JS Bajaj","year":"2014","unstructured":"Bajaj JS, Heuman DM, et al. Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. Aliment Pharmacol Ther. 2014;39(10):1113\u201325.","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"753_CR102","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s11894-018-0636-7","volume":"20","author":"N Bhutiani","year":"2018","unstructured":"Bhutiani N, Schucht JE, et al. Technical aspects of fecal microbial transplantation (FMT) [j]. Curr Gastroenterol Rep. 2018;20(7):30.","journal-title":"Curr Gastroenterol Rep"},{"issue":"9","key":"753_CR103","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/apt.13144","volume":"41","author":"G Cammarota","year":"2015","unstructured":"Cammarota G, Masucci L, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2015;41(9):835\u201343.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"753_CR104","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/apt.14201","volume":"46","author":"MN Quraishi","year":"2017","unstructured":"Quraishi MN, Widlak M, et al. Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Aliment Pharmacol Ther. 2017;46(5):479\u201393.","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"753_CR105","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1177\/2050640618780762","volume":"6","author":"G Ianiro","year":"2018","unstructured":"Ianiro G, Maida M, et al. Efficacy of different faecal microbiota transplantation protocols for Clostridium difficile infection: a systematic review and meta-analysis. United Eur Gastroenterol J. 2018;6(8):1232\u201344.","journal-title":"United Eur Gastroenterol J"},{"issue":"10","key":"753_CR106","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1080\/14737175.2023.2250919","volume":"23","author":"GG Zhanel","year":"2023","unstructured":"Zhanel GG, Keynan R, et al. The role of fecal microbiota transplantation (FMT) in treating patients with multiple sclerosis. Expert Rev Neurother. 2023;23(10):921\u201330.","journal-title":"Expert Rev Neurother"},{"issue":"9","key":"753_CR107","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1136\/annrheumdis-2020-219511","volume":"80","author":"MS Kragsnaes","year":"2021","unstructured":"Kragsnaes MS, Kjeldsen J, et al. Safety and efficacy of faecal microbiota transplantation for active peripheral psoriatic arthritis: an exploratory randomised placebo-controlled trial [J]. Ann Rheum Dis. 2021;80(9):1158\u201367.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"753_CR108","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1002\/ccr3.3677","volume":"9","author":"J Zeng","year":"2021","unstructured":"Zeng J, Peng L, et al. Fecal microbiota transplantation for rheumatoid arthritis: a case report. Clin Case Rep. 2021;9(2):906\u20139.","journal-title":"Clin Case Rep"},{"issue":"7","key":"753_CR109","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.14309\/ajg.0000000000000115","volume":"114","author":"JR Allegretti","year":"2019","unstructured":"Allegretti JR, Kassam Z, et al. Fecal microbiota transplantation in patients with primary sclerosing cholangitis: a pilot clinical trial [J]. Am J Gastroenterol. 2019;114(7):1071\u20139.","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"753_CR110","first-page":"1148","volume":"27","author":"R Chen","year":"2024","unstructured":"Chen R, Wu F, et al. Therapeutic effect of fecal microbiota transplantation on rats with liver cirrhosis and its influence on gut microbiota [J]. Iran J Basic Med Sci. 2024;27(9):1148\u201354.","journal-title":"Iran J Basic Med Sci"},{"issue":"4","key":"753_CR111","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1002\/hep.30037","volume":"68","author":"JS Bajaj","year":"2018","unstructured":"Bajaj JS, Kakiyama G, et al. Antibiotic-associated disruption of microbiota composition and function in cirrhosis is restored by fecal transplant. Hepatology. 2018;68(4):1549\u201358.","journal-title":"Hepatology"},{"issue":"6","key":"753_CR112","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s12664-018-0906-1","volume":"37","author":"R Mehta","year":"2018","unstructured":"Mehta R, Kabrawala M, et al. Preliminary experience with single fecal microbiota transplant for treatment of recurrent overt hepatic encephalopathy-a case series. Indian J Gastroenterol. 2018;37(6):559\u201362.","journal-title":"Indian J Gastroenterol"},{"issue":"4","key":"753_CR113","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.cgh.2016.10.029","volume":"15","author":"CA Philips","year":"2017","unstructured":"Philips CA, Pande A, et al. Healthy donor fecal microbiota transplantation in steroid-ineligible severe alcoholic hepatitis: a pilot study. Clin Gastroenterol Hepatol. 2017;15(4):600\u20132.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"753_CR114","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.coph.2019.04.008","volume":"49","author":"FE Dailey","year":"2019","unstructured":"Dailey FE, Turse EP, et al. The dirty aspects of fecal microbiota transplantation: a review of its adverse effects and complications. Curr Opin Pharmacol. 2019;49:29\u201333.","journal-title":"Curr Opin Pharmacol"},{"issue":"1","key":"753_CR115","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/19490976.2020.1854640","volume":"12","author":"JE Green","year":"2020","unstructured":"Green JE, Davis JA, et al. Efficacy and safety of fecal microbiota transplantation for the treatment of diseases other than Clostridium difficile infection: a systematic review and meta-analysis [J]. Gut Microbes. 2020;12(1):1\u201325.","journal-title":"Gut Microbes"},{"issue":"Suppl 1","key":"753_CR116","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1016\/j.jfma.2018.08.011","volume":"118","author":"JW Wang","year":"2019","unstructured":"Wang JW, Kuo CH, et al. Fecal microbiota transplantation: Review and update [J]. J Formos Med Assoc. 2019;118(Suppl 1):S23-s31.","journal-title":"J Formos Med Assoc"},{"issue":"2","key":"753_CR117","doi-asserted-by":"publisher","first-page":"e0006022","DOI":"10.1128\/cmr.00060-22","volume":"37","author":"A Yadegar","year":"2024","unstructured":"Yadegar A, Bar-Yoseph H, et al. Fecal microbiota transplantation: current challenges and future landscapes. Clin Microbiol Rev. 2024;37(2):e0006022.","journal-title":"Clin Microbiol Rev"},{"issue":"4","key":"753_CR118","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1136\/gutjnl-2016-313017","volume":"66","author":"G Cammarota","year":"2017","unstructured":"Cammarota G, Ianiro G, et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut. 2017;66(4):569\u201380.","journal-title":"Gut"}],"container-title":["Gut Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13099-025-00753-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13099-025-00753-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13099-025-00753-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T17:21:49Z","timestamp":1762881709000},"score":1,"resource":{"primary":{"URL":"https:\/\/gutpathogens.biomedcentral.com\/articles\/10.1186\/s13099-025-00753-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":118,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["753"],"URL":"https:\/\/doi.org\/10.1186\/s13099-025-00753-w","relation":{},"ISSN":["1757-4749"],"issn-type":[{"value":"1757-4749","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"assertion":[{"value":"11 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential competing interests.The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"86"}}